PLoS ONE · 2020 · 25 citations · 23 references
MedicineHematologyNephrologyDialysisHemodialysisRenal Replacement TherapyAnemiaAnemia Management In HemodialysisChronic Kidney DiseaseRenal DiseaseRenal Function TestsRenal ImpairmentAnemia DiagnosisAnemia Management In DialysisAnemia Of CkdAnemia Of Kidney DiseaseChronic Kidney Disease EpidemiologyChronic Kidney Disease ManagementHemoglobin FunctionSevere Anemia
OBJECTIVES: Anemia is highly prevalent in chronic kidney disease patients; however, its identification and management have been reported to be suboptimal. In this study we aimed to describe the prevalence, severity, risk factors, and treatment of anemia in different nephrology centers, among chronic kidney disease patients who were not given renal replacement therapy. MATERIALS AND METHODS: We performed a multicenter cross-sectional study in three different nephrology clinics. Adult (>18 years of age) chronic kidney disease patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min, and who were not started dialysis were recruited. Demographic, clinical and laboratory data regarding anemia and its management were collected using a standard data form. Anemia was defined as a hemoglobin level below 12g/dL and severe anemia as a hemoglobin level below 10g/dl. RESULTS: A total of 1066 patients were enrolled in the study. Anemia and severe anemia were present in 55.9% and 14.9% of the patients, respectively. The mean hemoglobin level for the whole cohort was 11.8±1.8 g/dL. Univariate analyses revealed that the mean hemoglobin level was significantly different among the centers. Moreover, the frequency of the presence of anemia stratified by severity was also significantly different among the centers. According to binary logistic regression analysis, gender, levels of eGFR and iron, ferritin ≥ 100 ng/mL, and the nephrology center were independent determinants of severe anemia. CONCLUSIONS: We found a high prevalence of anemia among chronic kidney disease patients who were not on renal replacement therapy. Each center should determine the treatment strategy according to the patient's characteristics. According to our results, the center-specific management of anemia seems to be important.
23
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Marc A. Pfeffer, Emmanuel A. Burdmann, Chao Yin Chen et al. · New England Journal of Medicine · 2009 · 2.1K citations · Full text
Anaemia in low-income and middle-income countries
Yarlini Balarajan, Usha Ramakrishnan, Emre Özaltin et al. · The Lancet · 2011 · 1.3K citations